The therapeutic effect of guanxinning tablets combined with indapamide on patients with hypertension and coronary heart disease

doi:10.11958/20253569

Abstract

Abstract:

Objective To observe the effect of guanxinning tablets combined with indapamide in the treatment of hypertension with coronary heart disease, as well as its influences on the number of plasma circulating endothelial cells (CEC) and the serum level of energy balance protein Adropin in patients. Methods Totally 150 patients with hypertension and coronary heart disease were randomly assigned into the single-use group (indapamide sustained-release tablets) and the combined group (indapamide sustained-release tablets + guanxinning tablets) by random number table method, with 75 cases per group. The therapeutic effect, blood pressure, cardiac function indicators, endothelium-related indicators, hemorheology, lipid indicators, inflammatory indicators and changes in Adropin were observed and compared between the two groups. Results The total effective rate of the combined group was higher than that of the single-use group (P<0.05). After medication, the systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), endothelin-1 (ET-1), CEC, hematocrit (HCT), plasma viscosity (PV), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) were lower than those before medication in both groups, and the combined group was lower than the single-use group (P<0.05). After medication, the left ventricular ejection fraction (LVEF), nitric oxide (NO) and Adropin increased compared with those before medication in both groups, and the combined group was higher than the single-use group (P<0.05). There was no manifest difference in untoward reactions between the single-use group and the combined group during treatment (P>0.05). Conclusion Guanxinning tablets combined with indapamide have an ideal therapeutic effect on hypertension with coronary heart disease, and which can conspicuously improve the levels of CEC and Adropin in patients.

Key words: hypertension, coronary disease, Indapamide, endothelial cells, guanxinning tablets, Adropin

CLC Number:

R544.1

Figures/Tables 7

References 26

[1]	孙慧, 花继平. 美托洛尔联合心脉通胶囊对老年冠心病患者血脂、心功能及血液流变学的影响分析[J]. 中南医学科学杂志, 2020, 48(1):18-21.
	SUN H, HUA J P. Effect of metoprolol combined with Xinmaitong Capsule on blood lipid,cardiac function and hemorheology in elderly patients with coronary heart disease[J]. Medical Science Journal of Central South China, 2020, 48(1):18-21. doi:10.15972/j.cnki.43-1509/r.2020.01.005.
[2]	褚敏, 高彦彩, 李磊, 等. 活血散风针刺法对冠心病伴高血压患者PCI围术期血压、术后血管内皮功能及冠脉再狭窄风险的影响[J]. 辽宁中医杂志, 2025, 52(5):97-100.
	CHU M, GAO Y C, LI L, et al. Effect of acupuncture for promoting blood circulation and dispersing windon blood pressure in perioperative period of PCI,postoperative vascular endothelial function and risk of coronary restenosis in patients with coronary heart disease and hypertension[J]. Liaoning J Tradit Chin Med, 2025, 52(5):97-100. doi:10.13192/j.issn.1000-1719.2025.05.027.
[3]	高肖坤, 马佳佳, 武晓玲, 等. 高血压合并冠心病患者血管紧张素Ⅱ和可溶性细胞间黏附分子-1与左心室肥厚的相关性[J]. 中华高血压杂志, 2025, 33(10):974-978.
	GAO X K, MA J J, WU X L, et al. The correlation between angiotensin II,soluble intercellular adhesion molecule-1,and left ventricular hypertrophy in patients with hypertension complicated by coronary heart disease[J]. Chin J Hypertens, 2025, 33(10):974-978. doi:10.16439/j.issn.1673-7245.2024-0392.
[4]	陈俊民, 郭瑞瑞, 高燕, 等. 阿托伐他汀钙片联合吲达帕胺对高血压合并冠心病患者血清血管活性肽N末端脑钠肽前体的影响[J]. 山西医药杂志, 2020, 49(21):2961-2964.
	CHEN J M, GUO R R, GAO Y, et al. The effect of atorvastatin calcium tablets combined with indapamide on serum vasoactive peptide N-terminal pro-brain natriuretic peptide in patients with hypertension complicated by coronary heart disease[J]. Shanxi Med J, 2020, 49(21):2961-2964. doi:10.3969/j.issn.0253-9926.2020.21.029.
[5]	庄惊奇, 徐颖, 祁超静, 等. 脑立清胶囊联合吲达帕胺治疗高血压合并冠心病的效果及对PPAR-γ、MCP-1、ADMA水平的影响[J]. 临床医学研究与实践, 2023, 8(32):124-127.
	ZHUANG J Q, XU Y, QI C J, et al. Effect of Naoliqing capsule combined with indapamide in the treatment of hypertension complicated with coronary heart disease and its influences on PPAR-γ,MCP-1 and ADMA levels[J]. Clinical Research and Practice, 2023, 8(32):124-127. doi:10.19347/j.cnki.2096-1413.202332031.
[6]	陈铁军, 陈婕, 王肖龙, 等. 冠心病患者中医证型与其冠状动脉血管病变特点和程度的关系[J]. 医学综述, 2020, 26(4):782-785,791.
	CHEN T J, CHEN J, WANG X L, et al. Relationship of traditional Chinese medicine syndromes of coronary heart disease with characteristics and degree of coronary angiopathy[J]. Med Recapitulate, 2020, 26(4):782-785,791. doi:10.3969/j.issn.1006-2084.2020.04.031.
[7]	吴子政, 陈杏, 叶嘉豪, 等. 基于网络药理学及实验验证探讨冠心宁注射液对冠心病大鼠的干预机制[J]. 湖南中医药大学学报, 2025, 45(6):1156-1168.
	WU Z Z, CHEN X, YE J H, et al. Intervention mechanism of Guanxinning Injection on rats with coronary heart disease based on network pharmacology and experimental verification[J]. J Hunan Univ Chin Med, 2025, 45(6):1156-1168. doi:10.3969/j.issn.1674-070X.2025.06.027.
[8]	孔祥慧, 田曦嘉, 马立庆. 磁共振联合血管性血友病因子与循环内皮细胞对冠心病患者左心室心功能的评估价值[J]. 中华老年心脑血管病杂志, 2023, 25(5):473-476.
	KONG X H, TIAN X J, MA L Q. Evaluation of left ventricular function in patients with CHD by magnetic resonance imaging combined with vWF and circulating endothelial cells[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2023, 25(5):473-476. doi:10.3969/j.issn.1009-0126.2023.05.007.
[9]	常先松, 金富璐, 王培育, 等. Adropin与心血管疾病的关系[J]. 河北医药, 2023, 45(4):601-605.
	CHANG X S, JIN F L, WANG P Y, et al. Relationship between Adropin and cardiovascular disease[J]. Hebei Medical Journal, 2023, 45(4):601-605. doi:10.3969/j.issn.1002-7386.2023.04.030.
[10]	颜红兵, 马长生, 霍勇. 临床冠心病诊断与治疗指南[M]. 北京: 人民卫生出版社,2010:22-26.
	YAN H B, MA C S, HUO Y. Guidelines for diagnosis and treatment of clinical coronary heart disease[M]. Beijing: People's Medical Publishing House,2010:22-26.
[11]	中国高血压防治指南修订委员会. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治, 2019, 19(1):1-44.
	Revision Committee of Guidelines for Prevention and Treatment of Hypertension in China. Guidelines for the Prevention and Treatment of Hypertension in China(2018 Revision)[J]. Cardio-cerebrovasc Dis Prev Treat, 2019, 19(1):1-44. doi:10.3969/j.issn.1009-816X.2019.01.001.
[12]	中华中医药学会心血管病分会. 冠心病稳定型心绞痛中医诊疗指南[J]. 中医杂志, 2019, 60(21):1880-1890.
	Cardiovascular Disease Branch of China Association of Traditional Chinese Medicine. Guidelines for the Diagnosis and Treatment of Stable Angina Pectoris in Coronary Heart Disease with Traditional Chinese Medicine[J]. J Tradit Chin Med, 2019, 60(21):1880-1890. doi:10.13288/j.11-2166/r.2019.21.015.
[13]	周德伟, 夏莉, 吴家明. 血清25-羟维生素D3与老年高血压及其分级、心血管综合风险分层的相关性[J]. 分子诊断与治疗杂志, 2023, 15(8):1366-1369,1374.
	ZHOU D W, XIA L, WU J M. Correlation between serum 25 hydroxyvitamin D3 and geriatric hypertension and its grading,cardiovascular comprehensive risk stratification[J]. Journal of Molecular Diagnosis and Therapy, 2023, 15(8):1366-1369,1374. doi:10.3969/j.issn.1674-6929.2023.08.021.
[14]	程航, 杨向东, 李帆, 等. 吲达帕胺联合贝那普利对2级原发性高血压患者血管内皮功能及心血管活性肽Salusins水平的影响[J]. 中国药业, 2022, 31(11):86-89.
	CHENG H, YANG X D, LI F, et al. Effect of Indapamide combined with Benazepril on vascular endothelial function and level of cardiovascular active peptide salusins in patients with grade-Ⅱ essential hypertension[J]. China Pharmaceuticals, 2022, 31(11):86-89. doi:10.3969/j.issn.1006-4931.2022.11.022.
[15]	李秀, 王兰兰, 马文涛. 吲达帕胺结合氨氯地平片对高血压伴冠心病患者血压水平、心功能指标的影响[J]. 中外医疗, 2024, 43(17):81-84.
	LI X, WANG L L, MA W T. Effect of Indapamide combined with Amlodipine tablet on blood pressure level and cardiac function index in patients with hypertension and coronary heart disease[J]. China Foreign Medical Treatment, 2024, 43(17):81-84. doi:10.16662/j.cnki.1674-0742.2024.17.081.
[16]	尚菊菊, 刘红旭, 李享. 基于指南/共识探讨中医/中西医结合防治冠心病的诊疗进展[J]. 北京中医药, 2023, 42(9):939-942.
	SHANG J J, LIU H X, LI X. Progress in diagnosis and treatment of coronary heart disease with integrated traditional Chinese and Western Medicine[J]. Beijing Journal of Traditional Chinese Medicine, 2023, 42(9):939-942. doi:10.16025/j.1674-1307.2023.09.002.
[17]	赵玉涵, 肖光旭, 范斯文, 等. 丹参-川芎药对治疗心脑血管疾病的作用机制及临床研究[J]. 中国动脉硬化杂志, 2022, 30(6):461-469.
	ZHAO Y H, XIAO G X, FAN S W, et al. Mechanism and clinical study of Danshen-Chuanxiong herbal pair in the treatment of cardiovascular and cerebrovascular diseases[J]. Chinese Journal of Arteriosclerosis, 2022, 30(6):461-469. doi:10.3969/j.issn.1007-3949.2022.06.001.
[18]	王洋, 刘悦, 孔德昭, 等. 基于"脾气散精"理论探讨从脾论治冠心病调节血脂水平效果研究[J]. 辽宁中医药大学学报, 2022, 24(2):41-44.
	WANG Y, LIU Y, KONG D Z, et al. Based on the theory of "Spleen-Qi Transporting the Essence to the Whole Body" to explore the effect of regulating blood lipid level in treating coronary heart disease from the spleen[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2022, 24(2):41-44. doi:10.13194/j.issn.1673-842x.2022.02.010.
[19]	BABAKR A, MUKHTAR M, ALTHUBITI M, et al. Investigation of hyperlipidemia associated with increased levels of oxidized low-density lipoproteins and 8-hydroxy-2´-deoxyguanosine[J]. Diabetes Metab Syndr Obes, 2023, 16:447-455. doi:10.2147/DMSO.S396676.
[20]	姚惠, 张清文, 朱坤. 冠心宁注射液联合酒石酸美托洛尔片治疗冠心病心绞痛的效果观察[J]. 世界中医药, 2020, 15(18):2751-2754.
	YAO H, ZHANG Q W, ZHU K. Observation on the effects of Guanxinning Injection combined with Metoprolol Tartrate on angina pectoris of coronary heart disease[J]. World Chin Med, 2020, 15(18):2751-2754. doi:10.3969/j.issn.1673-7202.2020.18.015.
[21]	杨海龙, 张炜, 谢润阳. 高血压合并冠心病患者血清8-OHdG、Adropin水平及其对PCI后发生主要不良心血管事件的预测价值[J]. 检验医学与临床, 2025, 22(16):2195-2201.
	YANG H L, ZHANG W, XIE R Y. Serum 8-OHdG and Adropin levels in patients with hypertension complicating coronary heart disease and their predictive value for major adverse cardiovascular events occurrence after PCI[J]. Lab Med Clin, 2025, 22(16):2195-2201. doi:10.3969/j.issn.1672-9455.2025.16.007.
[22]	RAMOS-ARELLANO L E, MATIA-GARCIA I, MARINO-ORTEGA L A, et al. Obesity,dyslipidemia,and high blood pressure are associated with cardiovascular risk,determined using high-sensitivity C-reactive protein concentration,in young adults[J]. J Int Med Res, 2020, 48(12):300060520980596. doi:10.1177/0300060520980596.
[23]	LI B, WANG Z, HE Y, et al. Adropin improves radiation-induced myocardial injury via VEGFR2/PI3K/Akt pathway[J]. Oxid Med Cell Longev, 2022, 2022:8230214. doi:10.1155/2022/8230214.
[24]	GOHBARA M, IWAHASHI N, NAKAHASHI H, et al. Clinical impact of admission urinary 8-hydroxydeoxyguanosine level for predicting cardiovascular mortality in patients with acute coronary syndrome[J]. Heart Vessels, 2021, 36(1):38-47. doi:10.1007/s00380-020-01663-4.
[25]	张泽骅, 任明. Adropin蛋白在心血管疾病中的临床研究进展[J]. 中华老年心脑血管病杂志, 2018, 20(2):205-207.
	ZHANG Z H, REN M. Clinical research progress of Adropin protein in cardiovascular diseases[J]. Chin J Geriatr Heart Brain Vessel Dis, 2018, 20(2):205-207. doi:10.3969/j.issn.1009-0126.2018.02.026.
[26]	田祖云. 冠心宁片联合西药治疗冠心病合并轻度高血压病临床研究[J]. 新中医, 2022, 54(18):35-39.
	TIAN Z Y. Clinical study on Guanxinning Tablets combined with Western Medicine for coronary heart disease complicated with mild hypertension[J]. Journal of New Chinese Medicine, 2022, 54(18):35-39. doi:10.13457/j.cnki.jncm.2022.18.008.

组别	性别				年龄/岁		体质量指数/（kg/m²）		病程/年		心功能分级			高血压分级^[13]
组别	男		女		年龄/岁		体质量指数/（kg/m²）		病程/年		Ⅰ级		Ⅱ级	1级		2级
单用组	37（49.33）		38（50.67）		60.35±6.35		22.39±2.17		7.16±2.01		42（56.00）		33（44.00）	44（58.67）		31（41.33）
联合组	35（46.47）		40（53.33）		61.57±5.28		22.07±2.83		7.65±2.31		45（60.00）		30（40.00）	42（56.00）		33（44.00）
t或χ²	0.107				1.287		0.803		1.396		0.246			0.109
组别		合并用药史						冠脉病变				空腹血糖/（mmol/L）			糖化血红蛋白/%
组别		他汀类		β受体阻滞剂		ACEI/ARB类		单支		多支		空腹血糖/（mmol/L）			糖化血红蛋白/%
单用组		38（50.67）		41（54.67）		44（58.67）		28（37.33）		47（62.67）		5.82±0.71			5.65±0.43
联合组		35（46.67）		39（52.00）		46（61.33）		26（34.67）		49（65.33）		5.79±0.68			5.71±0.39
χ²		0.240		0.107		0.111		1.291				0.262			1.049

组别	性别				年龄/岁		体质量指数/（kg/m²）		病程/年		心功能分级			高血压分级^[13]
组别	男		女		年龄/岁		体质量指数/（kg/m²）		病程/年		Ⅰ级		Ⅱ级	1级		2级
单用组	37（49.33）		38（50.67）		60.35±6.35		22.39±2.17		7.16±2.01		42（56.00）		33（44.00）	44（58.67）		31（41.33）
联合组	35（46.47）		40（53.33）		61.57±5.28		22.07±2.83		7.65±2.31		45（60.00）		30（40.00）	42（56.00）		33（44.00）
t或χ²	0.107				1.287		0.803		1.396		0.246			0.109
组别		合并用药史						冠脉病变				空腹血糖/（mmol/L）			糖化血红蛋白/%
组别		他汀类		β受体阻滞剂		ACEI/ARB类		单支		多支		空腹血糖/（mmol/L）			糖化血红蛋白/%
单用组		38（50.67）		41（54.67）		44（58.67）		28（37.33）		47（62.67）		5.82±0.71			5.65±0.43
联合组		35（46.67）		39（52.00）		46（61.33）		26（34.67）		49（65.33）		5.79±0.68			5.71±0.39
χ²		0.240		0.107		0.111		1.291				0.262			1.049

项目	显效	有效	无效
临床症状	消失	改善	明显
心绞痛、眩晕发作次数	减少≥80%	减少≥50%，<80%	未达上述标准
舒张压	降低>20 mmHg或正常	降低10~20 mmHg
硝酸甘油用量	减少≥80%	减少50%~79%
SAQ评分	≥80分	60~79分	<60分

项目	显效	有效	无效
临床症状	消失	改善	明显
心绞痛、眩晕发作次数	减少≥80%	减少≥50%，<80%	未达上述标准
舒张压	降低>20 mmHg或正常	降低10~20 mmHg
硝酸甘油用量	减少≥80%	减少50%~79%
SAQ评分	≥80分	60~79分	<60分

组别	显效/例	有效/例	无效/例	总有效率/%
单用组	26	30	19	74.67
联合组	32	37	6	92.00
χ²				8.112^＊＊